Learn more about Rejoyn

Rejoyn is 6 weeks of structured brain training that's designed to improve emotion regulation and processing.1

  • A small, blue illustration of a brain appears

    Rejoyn has 2 key components:
    cognitive emotional training
    exercises for the brain and
    cognitive behavioral therapy-
    based lessons.1

  • A blue zero with a line through the center indicates zero side effects from Rejoyn

    In a clinical trial, adding
    Rejoyn to an antidepressant
    reduced symptoms of
    MDD with zero adverse
    events related to Rejoyn.1

  • A blue down arrow above a horizontal line indicates that Rejoyn can be downloaded

    Rejoyn will be available to
    download in the App Store®
    and Google Play™ store in
    summer 2024.2

Find out more in the press release for Rejoyn

App Store is a service mark of Apple Inc., registered in the United States and other countries.
Google Play and the Google Play logo are trademarks of Google LLC.

INDICATION: Rejoyn is a prescription digital therapeutic for the treatment of Major Depressive Disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. It is intended to reduce MDD symptoms.

SAFETY INFORMATION: Rejoyn is not intended to be used as a standalone therapy or a substitute for medication. Patients should continue their current treatment as directed.

Rejoyn does not monitor the patient's symptoms or clinical status and cannot send or receive alerts or warnings to the prescriber. Patients should be clearly instructed that if they believe their depression is worsening or if they have feelings or thoughts of harming themselves or others, to contact a healthcare professional, dial 911 or go to the nearest emergency room immediately.